NO323553B1 - Fremgangsmate for tilvirkning og bruk av pyrrolopyrimidinon-derivater - Google Patents

Fremgangsmate for tilvirkning og bruk av pyrrolopyrimidinon-derivater Download PDF

Info

Publication number
NO323553B1
NO323553B1 NO20023823A NO20023823A NO323553B1 NO 323553 B1 NO323553 B1 NO 323553B1 NO 20023823 A NO20023823 A NO 20023823A NO 20023823 A NO20023823 A NO 20023823A NO 323553 B1 NO323553 B1 NO 323553B1
Authority
NO
Norway
Prior art keywords
ch2ch2ch3
pyrrolo
dihydro
ylsulfonyl
pyrimidin
Prior art date
Application number
NO20023823A
Other languages
English (en)
Norwegian (no)
Other versions
NO20023823D0 (no
NO20023823L (no
Inventor
Dae-Kee Kim
Ju Young Lee
Do Hyun Ryu
Nam Kyu Lee
Suk Ho Lee
Nam-Ho Kim
Jae-Sun Kim
Je Ho Ryu
Jin-Young Choi
Guang-Jin Im
Won-Son Choi
Tae Kon Kim
Hoon Cha
Original Assignee
Sk Chemicals Co Ltd
In2Gen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Chemicals Co Ltd, In2Gen Co Ltd filed Critical Sk Chemicals Co Ltd
Publication of NO20023823D0 publication Critical patent/NO20023823D0/no
Publication of NO20023823L publication Critical patent/NO20023823L/no
Publication of NO323553B1 publication Critical patent/NO323553B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
NO20023823A 2000-02-17 2002-08-13 Fremgangsmate for tilvirkning og bruk av pyrrolopyrimidinon-derivater NO323553B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20000007625A KR100358083B1 (ko) 2000-02-17 2000-02-17 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도
PCT/KR2001/000227 WO2001060825A1 (en) 2000-02-17 2001-02-15 Pyrrolopyrimidinone derivatives, process of preparation and use

Publications (3)

Publication Number Publication Date
NO20023823D0 NO20023823D0 (no) 2002-08-13
NO20023823L NO20023823L (no) 2002-10-09
NO323553B1 true NO323553B1 (no) 2007-06-11

Family

ID=19647449

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023823A NO323553B1 (no) 2000-02-17 2002-08-13 Fremgangsmate for tilvirkning og bruk av pyrrolopyrimidinon-derivater

Country Status (23)

Country Link
US (1) US6962911B2 (pt)
EP (1) EP1257553B1 (pt)
JP (1) JP4845076B2 (pt)
KR (1) KR100358083B1 (pt)
CN (1) CN1312153C (pt)
AT (1) ATE267829T1 (pt)
AU (2) AU2001236140B9 (pt)
BR (1) BRPI0108395B8 (pt)
CA (1) CA2400268C (pt)
DE (1) DE60103508T2 (pt)
DK (1) DK1257553T3 (pt)
ES (1) ES2222344T3 (pt)
HU (1) HU230344B1 (pt)
IL (2) IL151234A0 (pt)
MX (1) MXPA02007942A (pt)
NO (1) NO323553B1 (pt)
NZ (1) NZ520842A (pt)
PL (1) PL210796B1 (pt)
PT (1) PT1257553E (pt)
RU (1) RU2263676C2 (pt)
TR (1) TR200402101T4 (pt)
WO (1) WO2001060825A1 (pt)
ZA (1) ZA200206587B (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100358083B1 (ko) * 2000-02-17 2002-10-25 에스케이케미칼주식회사 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도
EP1362858A1 (en) * 2002-05-15 2003-11-19 SK Chemicals Co., Ltd. Pyrrolopyrimidinone derivates, process of preparation and use
DE10229778A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Neue Verwendung von Imidazotriazinonen
FR2842809A1 (fr) * 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
CN100374441C (zh) * 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
TW200745106A (en) * 2005-10-03 2007-12-16 Astrazeneca Ab Chemical compounds
CA2666696C (en) * 2006-07-03 2013-01-15 Sk Chemicals Co., Ltd. Salts of pyrrolopyrimidinone derivatives and process for preparing the same
KR20080003599A (ko) * 2006-07-03 2008-01-08 에스케이케미칼주식회사 피롤로피리미디논 유도체의 겐티세이트 염 및 이의제조방법
KR101002490B1 (ko) * 2007-06-09 2010-12-17 동아제약주식회사 유데나필을 유효성분으로 함유하는 만성 심부전증 치료용약학적 조성물
NZ599290A (en) 2009-10-16 2014-10-31 Melinta Therapeutics Inc Antimicrobial compounds and methods of making and using the same
EA201270566A1 (ru) 2009-10-16 2012-11-30 Риб-Экс Фармасьютикалз, Инк. Противомикробные соединения и способы их получения и применения
MX2012004341A (es) 2009-10-16 2012-10-05 Rib X Pharmaceuticals Inc Compuestos antimicrobianos y metodos para fabricar y utilizar los mismos.
CN102970965A (zh) 2010-04-05 2013-03-13 Sk化学公司 含有pde5抑制剂的减少皮肤皱纹的合成物
CN102372730B (zh) * 2010-08-19 2014-03-26 山东轩竹医药科技有限公司 桥环取代的磷酸二酯酶抑制剂
CN102134242B (zh) * 2011-01-21 2013-08-28 浙江大德药业集团有限公司 一种用于治疗阳痿的快速长效的化合物
TWI490220B (zh) * 2011-04-04 2015-07-01 Sk Chemicals Co Ltd 包含ｐｄｅ５抑制劑之用於減少皮膚皺紋之組成物
MY173518A (en) * 2011-04-15 2020-01-30 Melinta Therapeutics Inc Antimicrobial compounds and methods of making and using the same
CN103826638B (zh) 2011-09-09 2015-11-25 Sk化学公司 含有pde5 抑制剂的减少皮肤皱纹的组合物
US9750743B2 (en) 2012-12-04 2017-09-05 Aribio Inc. Composition comprising phosphodiesterase type 5 inhibitor for inhibiting apoptosis of nerve cells
CA2923214A1 (en) 2013-09-09 2015-03-12 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
EP3038623A4 (en) 2013-09-09 2017-04-19 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
HK1249758A1 (zh) 2015-03-11 2018-11-09 Melinta Therapeutics, Inc. 抗微生物化合物及其制备和使用方法
CN104744478B (zh) * 2015-03-20 2016-08-24 中国人民解放军第二军医大学 一种防治辐射损伤的化合物、单晶及其制备方法和应用
PL3377495T3 (pl) 2015-11-16 2022-05-16 Topadur Pharma Ag Pochodne 2-fenylo-3,4-dihydropirolo[2,1-f] [1,2,4]triazynonu jako inhibitory fosfodiesterazy i ich zastosowania
US11098047B2 (en) 2016-05-06 2021-08-24 BioVersys AG Antimicrobials and methods of making and using same
KR102670626B1 (ko) * 2017-05-22 2024-05-29 토파두르 파마 아게 가용성 구아닐레이트 사이클라제 활성제 및 포스포디에스테라제 억제제의 신규한 이중 작용 방식 및 이의 용도
JP7596257B2 (ja) * 2018-08-06 2024-12-09 ニコックス エス．エー． 一酸化窒素放出性ホスホジエステラーゼ５型阻害薬
WO2020109354A1 (en) 2018-11-28 2020-06-04 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
KR102271305B1 (ko) 2020-05-21 2021-06-30 주식회사 아리바이오 치매 예방 및 치료용 조성물
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
KR102900330B1 (ko) * 2020-07-16 2025-12-15 제이투에이치바이오텍 (주) 이중 억제제 화합물 및 이들의 의약 용도
CN111825593B (zh) * 2020-08-19 2023-04-07 上海成澄科技有限公司 3-氨基吡咯-2-甲酰胺类化合物的合成方法
KR102272907B1 (ko) 2020-11-05 2021-07-05 주식회사 아리바이오 치매 예방 및 치료용 조성물
KR102272910B1 (ko) 2021-01-28 2021-07-06 주식회사 아리바이오 당뇨병을 동반한 치매 예방 및 치료용 조성물
KR20220140960A (ko) 2021-04-12 2022-10-19 주식회사 아리바이오 당뇨병을 동반한 치매 예방 및 치료용 조성물
KR102311224B1 (ko) 2021-04-23 2021-10-13 주식회사 아리바이오 Pde5 억제제와 글루코코르티코이드 수용체 길항제 병용투여를 통한 치매 예방 및 치료용 조성물
KR20220146095A (ko) 2021-04-23 2022-11-01 주식회사 아리바이오 Pde5 억제제와 글루코코르티코이드 수용체 길항제 병용투여를 통한 치매 예방 및 치료용 조성물
CA3228160A1 (en) 2021-09-29 2023-04-06 Topadur Pharma Ag Topical compositions of 2-phenyl-3,4-dihydropyrrolo[2,l-f] [1,2,4]triazinone derivatives and uses thereof
JP2025506878A (ja) 2022-03-02 2025-03-13 トパデュール ファルマ アーゲー 局所組成物及びその使用
KR20230129639A (ko) 2022-03-02 2023-09-11 연세대학교 산학협력단 이중작용 pde5 억제제/질산유기에스터의 국소 혈류 증진을 위한 경피 투약 형태
KR20240117491A (ko) 2023-01-25 2024-08-01 주식회사 아리바이오 포스포디에스테라제 타입 ５ 저해제를 유효성분으로 포함하는 외상 후 스트레스 장애의 예방 또는 치료용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5761734B2 (pt) * 1973-09-27 1982-12-25 Takeda Chemical Industries Ltd
JPS5761734A (en) * 1980-10-02 1982-04-14 Teijin Ltd Spun like fabric
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US5236926A (en) * 1992-02-03 1993-08-17 Warner-Lambert Company 9-substituted-8-halo or -8-hydroxy-9-deazaguanines as inhibitors or PNP for pharmaceutical compositions
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
JP3713783B2 (ja) * 1995-01-20 2005-11-09 大正製薬株式会社 １Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体
RU2097394C1 (ru) * 1996-02-06 1997-11-27 Открытое акционерное общество "Акрон" Пресс-масса для изготовления древесно-стружечных плит
EP0977756A1 (en) * 1997-04-25 2000-02-09 Pfizer Limited PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION
HRP20000712A2 (en) * 1998-04-20 2001-06-30 Pfizer PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
KR100358083B1 (ko) * 2000-02-17 2002-10-25 에스케이케미칼주식회사 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도

Also Published As

Publication number Publication date
ATE267829T1 (de) 2004-06-15
EP1257553A1 (en) 2002-11-20
DK1257553T3 (da) 2004-10-04
NO20023823D0 (no) 2002-08-13
PL358188A1 (en) 2004-08-09
IL151234A0 (en) 2003-04-10
PL210796B1 (pl) 2012-03-30
RU2263676C2 (ru) 2005-11-10
DE60103508D1 (de) 2004-07-01
AU2001236140B9 (en) 2006-08-31
RU2002124872A (ru) 2004-01-10
AU3614001A (en) 2001-08-27
HU230344B1 (hu) 2016-02-29
US20030171361A1 (en) 2003-09-11
JP2003523344A (ja) 2003-08-05
KR20010083637A (ko) 2001-09-01
WO2001060825A1 (en) 2001-08-23
AU2001236140B2 (en) 2006-01-12
HUP0300527A3 (en) 2012-10-29
DE60103508T2 (de) 2005-06-30
BRPI0108395B1 (pt) 2017-06-06
KR100358083B1 (ko) 2002-10-25
BR0108395A (pt) 2003-03-11
BRPI0108395B8 (pt) 2021-05-25
EP1257553B1 (en) 2004-05-26
ES2222344T3 (es) 2005-02-01
CA2400268A1 (en) 2001-08-23
CN1312153C (zh) 2007-04-25
HUP0300527A2 (hu) 2003-07-28
NZ520842A (en) 2004-04-30
MXPA02007942A (es) 2004-09-10
IL151234A (en) 2010-05-17
US6962911B2 (en) 2005-11-08
TR200402101T4 (tr) 2004-10-21
ZA200206587B (en) 2003-10-09
PT1257553E (pt) 2004-10-29
NO20023823L (no) 2002-10-09
CA2400268C (en) 2009-08-18
JP4845076B2 (ja) 2011-12-28
CN1422271A (zh) 2003-06-04

Similar Documents

Publication Publication Date Title
NO323553B1 (no) Fremgangsmate for tilvirkning og bruk av pyrrolopyrimidinon-derivater
AU2001236140A1 (en) Pyrrolopyrimidinone derivatives, process of preparation and use
JP3000674B2 (ja) ジヒドロピラゾロピロール類
AU636816B2 (en) Pyrazolopyrimidinone antianginal agents
US5346901A (en) Pyrazolopyrimidinone antianginal agents
US6235742B1 (en) 5-substituted pyrazolo[4,3-D]pyrimidin-7-ones
AU2020207089A1 (en) 15-PGDH inhibitor
US7501438B2 (en) Pyridoimidazole derivatives
NO178029B (no) Analogifremgangsmåte ved fremstilling av terapeutisk aktive pyrazolopyrimidinoner
CZ20012697A3 (cs) Deriváty pyrazolkarboxylové kyseliny, způsob jejich přípravy a farmaceutické prostředky, které je obsahují
CA1248532A (en) Pyrazolo¬3,4-b|pyridine derivatives and process for producing them
FI64597B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 5-ubstituerade 1,2-dihydro-3h-pyrrolo(1,2-a)pyrrol-1-karbox ylyror av motsvarande nya nitriler
KR20110028445A (ko) 퇴행성 및 염증성 질병의 치료에 유용한 축합된 피라진 화합물
IE922342A1 (en) Imidazo[2,1-b]benzothiazole-3-acetamide derivatives, their¹preparation and their use in therapeutics
WO2001087888A1 (en) Pyrazolopyrimidinone derivatives, process for their preparation and their use
KR100297814B1 (ko) 피라졸로피리미디논유도체와이의제조방법그리고이의용도
TWI300778B (en) Pyrrolopyrimidinone derivatives, process of preparation and use
US20050130983A1 (en) Pyrrolopyrimidinone derivatives, process for preparation thereof, and method of using and composition comprising them
US20010039347A1 (en) Process for preparing 8-cyclopentyl-6-ethyl-3-[substituted]-5,8-dihydro-4h-1,2,3a,7,8-pentaaza-as-indacenes and intermediates useful therein

Legal Events

Date Code Title Description
MK1K Patent expired